PMEL and melanoma: proposed a therapeutic multiepitope polypeptide consisting of HLA-A*02:01 restricted modified epitopes derived from different melanoma-associated antigens (gp100:209–217(210 M): IMDQVPFSV, gp100:280–288(288 V): YLEPGEVTV; Mart1:27–35(27 L): LAGIGILTV; tyrosinase: 368–376(370D): YMDGTMSQV) and showed the proteasomal-dependent efficacy in vitro using the peripheral blood mononuclear cells of healthy donors and patients undergoing treatment [30].